Alpine Immune Sciences Beheer

Beheer criteriumcontroles 3/4

De CEO Alpine Immune Sciences is Mitch Gold, benoemd in Jun2016, heeft een ambtstermijn van 7.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.92M, bestaande uit 20.5% salaris en 79.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.019% van de aandelen van het bedrijf, ter waarde € 791.58K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 6.1 jaar.

Belangrijke informatie

Mitch Gold

Algemeen directeur

US$2.9m

Totale compensatie

Percentage CEO-salaris	20.5%
Dienstverband CEO	7.9yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	6.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Mitch Gold's beloning veranderd ten opzichte van Alpine Immune Sciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$3m	US$599k	-US$32m
Sep 30 2023	n/a	n/a	-US$57m
Jun 30 2023	n/a	n/a	-US$59m
Mar 31 2023	n/a	n/a	-US$64m
Dec 31 2022	US$3m	US$544k	-US$58m
Sep 30 2022	n/a	n/a	-US$54m
Jun 30 2022	n/a	n/a	-US$54m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	US$3m	US$523k	-US$50m
Sep 30 2021	n/a	n/a	-US$42m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$1m	US$500k	-US$28m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$33m
Mar 31 2020	n/a	n/a	-US$35m
Dec 31 2019	US$2m	US$485k	-US$42m
Sep 30 2019	n/a	n/a	-US$47m
Jun 30 2019	n/a	n/a	-US$48m
Mar 31 2019	n/a	n/a	-US$44m
Dec 31 2018	US$1m	US$400k	-US$36m
Sep 30 2018	n/a	n/a	-US$30m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$2m	US$300k	-US$8m

Compensatie versus markt: De totale vergoeding ($USD 2.92M ) Mitch } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.92M ).

Compensatie versus inkomsten: De vergoeding van Mitch is gestegen terwijl het bedrijf verliesgevend is.

CEO

Mitch Gold (55 yo)

7.9yrs

Tenure

US$2,921,224

Compensatie

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mitchell Gold	Executive Chairman & CEO	7.9yrs	US$2.92m	0.019% € 791.6k
Stanford Peng	President and Head of Research & Development	5.1yrs	US$1.75m	0.43% € 17.7m
Paul Rickey	Senior VP	7.1yrs	US$1.28m	geen gegevens
Ulrich Fuhs	VP of Finance & Chief Accounting Officer	less than a year	geen gegevens	0.044% € 1.8m
M. Yi	Chief Technology Officer	less than a year	geen gegevens	geen gegevens
Michelle Greenblatt	Director of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Remy Durand	Chief Business Officer	4.3yrs	geen gegevens	0.15% € 6.1m
Andrew Sandler	Chief Medical Officer	1.8yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 34LA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mitchell Gold	Executive Chairman & CEO	9.3yrs	US$2.92m	0.019% € 791.6k
Robert Conway	Independent Director	6.8yrs	US$110.21k	0.073% € 3.0m
James Topper	Independent Director	7.9yrs	US$101.46k	0% € 0
Peter Thompson	Independent Director	7.9yrs	US$103.96k	0% € 0
Rafi Ahmed	Member of Scientific Advisory Board	5.5yrs	geen gegevens	geen gegevens
Xiangmin Cui	Independent Director	5.3yrs	US$100.21k	0% € 0
Andrew Scharenberg	Scientific Advisory Board Chairman	no data	geen gegevens	geen gegevens
Christopher Peetz	Independent Director	6.1yrs	US$98.96k	0.0028% € 113.6k
John Thompson	Member of Scientific Advisory Board	5.5yrs	geen gegevens	geen gegevens
Manish Butte	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Paul Tumeh	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
James Welsh	Member of Scientific Advisory Board	5.5yrs	geen gegevens	geen gegevens

6.1yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 34LA wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).

Alpine Immune Sciences Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. Announces Board Changes

Recent updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2023)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Alpine Immune Sciences, Inc Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Full year 2023 earnings released: US$0.64 loss per share (vs US$1.73 loss in FY 2022)

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Insufficient new directors

Insufficient new directors

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $149.9968 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

Alpine Immune Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

New major risk - Share price stability

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.60 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.25 loss in 1Q 2022)

Full year 2022 earnings released: US$1.73 loss per share (vs US$1.98 loss in FY 2021)

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. Provides Clinical Updates for Its Two Wholly Owned Programs, ALPN-303 and davoceticept

Second quarter 2022 earnings released: US$0.60 loss per share (vs US$0.46 loss in 2Q 2021)

Alpine Immune Sciences, Inc. Announces Board Changes

Alpine Immune Sciences Appoints Andrew S. Sandler as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

First quarter 2022 earnings released: US$0.25 loss per share (vs US$0.45 loss in 1Q 2021)

Alpine Immune Sciences, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting

Insufficient new directors

Alpine Immune Sciences, Inc. announced that it expects to receive $15 million in funding from Horizon Therapeutics Public Limited Company

Insufficient new directors

Third quarter 2021 earnings released: US$0.55 loss per share (vs US$0.28 loss in 3Q 2020)

Independent Director recently bought €84k worth of stock

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.53 loss in 2Q 2020)

Alpine Immune Sciences Announces First Patient Dosed in Synergy, Alpn-101 Phase 2 Lupus Clinical Trial and $45 Million in Development Milestones Achieved Under Abbvie Collaboration

Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at 2021 American Society of Clinical Oncology Virtual Annual Meeting

Alpine Immune Sciences, Inc. Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting

First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.30 loss in 1Q 2020)

Full year 2020 earnings released: US$1.34 loss per share (vs US$2.28 loss in FY 2019)

Alpine Immune Sciences, Inc. to Report Q4, 2020 Results on Mar 18, 2021

Alpine Immune Sciences, Inc. Announces Executive Changes

New 90-day high: €11.80

Alpine Immune Sciences Appoints Natasha A. Hernday to its Board of Directors

New 90-day high: €7.70

Independent Director recently bought €68k worth of stock

Third quarter 2020 earnings released: US$0.28 loss per share

Revenue misses expectations

Alpine Immune Sciences, Inc. to Report Q3, 2020 Results on Nov 12, 2020

First half earnings released

Alpine Immune Sciences, Inc. announced that it has received $60.000012 million in funding from a group of investors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd